Intravenous immune globulin therapy for early-onset sepsis in premature neonates - PubMed (original) (raw)
Clinical Trial
. 1992 Sep;121(3):434-43.
doi: 10.1016/s0022-3476(05)81802-5.
Affiliations
- PMID: 1517923
- DOI: 10.1016/s0022-3476(05)81802-5
Free article
Clinical Trial
Intravenous immune globulin therapy for early-onset sepsis in premature neonates
L E Weisman et al. J Pediatr. 1992 Sep.
Free article
Abstract
Newborn infants may have IgG deficiencies that increase their susceptibility to bacterial infection. To determine whether intravenous immune globulin (IVIG) therapy improves survival rates in early-onset sepsis, we prospectively entered 753 neonates (birth weight 500 to 2000 gm, gestation less than or equal to 34 weeks, age less than or equal to 12 hours) into a multicenter, double-blind, controlled trial. Blood culture specimens were obtained and infants randomly assigned to receive 10 ml (per kilogram) intravenously of a selected IVIG (500 mg/kg) or albumin (5 mg/kg) preparation. Maternal and neonatal risk factors were not different between groups. Thirty-one babies (4.2%) had early-onset sepsis; the causative organisms were group B streptococcus (12 babies), Escherichia coli (6), and others (13). Of these 31 neonates, 7 (23%) died. Total serum IgG was higher for 7 days after IVIG therapy than after albumin treatment (p less than 0.05). During these 7 days, 5 (30%) of 17 albumin-treated and none of 14 IVIG-treated patients died (p less than 0.05). The survival rate at 56 days of age, however, was not significantly improved. Group B streptococcus type-specific IgG antibody was significantly increased after IVIG treatment and appeared to be related to the amount of IVIG specific antibody. Infusion-related adverse reactions were less frequent in patients receiving IVIG therapy (0.5%) than in those receiving albumin. The IVIG therapy in neonates with early-onset sepsis, while reducing the early mortality rate, did not significantly affect the overall survival rate. Further studies are necessary to confirm these findings and to determine more effective therapeutic regimens.
Comment in
- Intravenous immune globulin therapy for sepsis in premature neonates.
Schreiber JR, Berger M. Schreiber JR, et al. J Pediatr. 1992 Sep;121(3):401-4. doi: 10.1016/s0022-3476(05)81794-9. J Pediatr. 1992. PMID: 1517915 No abstract available.
Similar articles
- Intravenous immune globulin prophylaxis of late-onset sepsis in premature neonates.
Weisman LE, Stoll BJ, Kueser TJ, Rubio TT, Frank CG, Heiman HS, Subramanian KN, Hankins CT, Cruess DF, Hemming VG, et al. Weisman LE, et al. J Pediatr. 1994 Dec;125(6 Pt 1):922-30. doi: 10.1016/s0022-3476(05)82011-6. J Pediatr. 1994. PMID: 7996367 Clinical Trial. - Directed immune globulin for the prevention or treatment of neonatal group B streptococcal infections: a review.
Fischer GW, Weisman LE, Hemming VG. Fischer GW, et al. Clin Immunol Immunopathol. 1992 Jan;62(1 Pt 2):S92-7. doi: 10.1016/0090-1229(92)90047-r. Clin Immunol Immunopathol. 1992. PMID: 1728993 - Comparison of group B streptococcal hyperimmune globulin and standard intravenously administered immune globulin in neonates.
Weisman LE, Anthony BF, Hemming VG, Fischer GW. Weisman LE, et al. J Pediatr. 1993 Jun;122(6):929-37. doi: 10.1016/s0022-3476(09)90023-3. J Pediatr. 1993. PMID: 8501574 Clinical Trial. - Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants.
Ohlsson A, Lacy JB. Ohlsson A, et al. Cochrane Database Syst Rev. 2004;(1):CD000361. doi: 10.1002/14651858.CD000361.pub2. Cochrane Database Syst Rev. 2004. PMID: 14973955 Updated. Review. - Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants.
Ohlsson A, Lacy JB. Ohlsson A, et al. Cochrane Database Syst Rev. 2001;(2):CD000361. doi: 10.1002/14651858.CD000361. Cochrane Database Syst Rev. 2001. PMID: 11405962 Updated. Review.
Cited by
- Demonstration of circulating group B streptococcal immune complexes in neonates with meningitis.
Vallejo JG, Baker CJ, Edwards MS. Vallejo JG, et al. J Clin Microbiol. 1994 Sep;32(9):2041-5. doi: 10.1128/jcm.32.9.2041-2045.1994. J Clin Microbiol. 1994. PMID: 7814522 Free PMC article. - Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock.
Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd. Alejandria MM, et al. Cochrane Database Syst Rev. 2013 Sep 16;2013(9):CD001090. doi: 10.1002/14651858.CD001090.pub2. Cochrane Database Syst Rev. 2013. PMID: 24043371 Free PMC article. Review. - Potential of immunomodulatory agents for prevention and treatment of neonatal sepsis.
Wynn JL, Neu J, Moldawer LL, Levy O. Wynn JL, et al. J Perinatol. 2009 Feb;29(2):79-88. doi: 10.1038/jp.2008.132. Epub 2008 Sep 4. J Perinatol. 2009. PMID: 18769381 Free PMC article. Review. - The INIS Study. International Neonatal Immunotherapy Study: non-specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo controlled, multicentre randomised trial.
INIS Study Collaborative Group. INIS Study Collaborative Group. BMC Pregnancy Childbirth. 2008 Dec 8;8:52. doi: 10.1186/1471-2393-8-52. BMC Pregnancy Childbirth. 2008. PMID: 19063731 Free PMC article. Clinical Trial. - Intravenous immunoglobulin for suspected or proven infection in neonates.
Ohlsson A, Lacy JB. Ohlsson A, et al. Cochrane Database Syst Rev. 2020 Jan 29;1(1):CD001239. doi: 10.1002/14651858.CD001239.pub6. Cochrane Database Syst Rev. 2020. PMID: 31995649 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical